Silence Therapeutics CEO Tooman to depart; Chairman Ross to lead on interim basis
Source: SeekingAlpha
2025-12-15 08:30:28 ET
More on Silence Therapeutics
- Silence Therapeutics: Divesiran Targets High-Burden PV
- Seeking Alpha’s Quant Rating on Silence Therapeutics
- Historical earnings data for Silence Therapeutics
- Financial information for Silence Therapeutics
Read the full article on Seeking Alpha
For further details see:
Silence Therapeutics CEO Tooman to depart; Chairman Ross to lead on interim basis
Silence Therapeutics Ord
NASDAQ: SLNCF
SLNCF Trading
0.0% G/L:
$2 Last:
1,200 Volume:
$2 Open:
SLNCF Latest News
March 05, 2026 07:30:00 am
Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results
November 12, 2025 08:00:00 am
Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference
November 06, 2025 07:30:00 am
Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
SLNCF Stock Data
$211,068,000
44,881,200
70.5%
10
N/A
Biotechnology & Life Sciences
Healthcare
GB
London
